The fire under GlaxoSmithKline's Emma Walmsley grows as another well-known activist investor grabs its pitchfork — report

Kyle Blankenship

Bluebell Capital Partners, a proxy brawler fresh off a campaign to oust global food giant Danone’s CEO and most of its board of directors, has bought a stake in UK drugmaker GlaxoSmithKline with its eyes trained directly on Emma Walmsley, the Financial Times reported Wednesday.

The London-based hedge fund joins another notorious activist firm in Paul Singer’s Elliott Management, which earlier this year called for a shakeup in leadership at GSK to handle what the company described as a wealth of riches across the drug giant’s portfolio hindered by limited vision from top staff.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

The fire under GlaxoSmithKline's Emma Walmsley grows as another well-known activist investor grabs its pitchfork — report

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

The fire un­der Glax­o­SmithK­line's Em­ma Walm­s­ley grows as an­oth­er well-known ac­tivist in­vestor grabs its pitch­fork — re­port

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

FDA ap­proves ma­jor de­pres­sive drug af­ter re­ject­ing it mul­ti­ple times in past two decades

Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

The fire under GlaxoSmithKline's Emma Walmsley grows as another well-known activist investor grabs its pitchfork — report

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them